Chromadex (NASDAQ:CDXC) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of Chromadex (NASDAQ:CDXC) from a buy rating to a hold rating in a report published on Tuesday morning, ValuEngine reports.

Separately, Zacks Investment Research raised shares of Chromadex from a sell rating to a hold rating in a research report on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Chromadex currently has a consensus rating of Hold and a consensus target price of $6.00.

CDXC traded up $0.12 during midday trading on Tuesday, hitting $3.65. The company had a trading volume of 136,480 shares, compared to its average volume of 210,413. Chromadex has a 52 week low of $2.79 and a 52 week high of $4.95. The company has a quick ratio of 1.11, a current ratio of 1.55 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $217.42 million, a price-to-earnings ratio of -5.98 and a beta of 1.38. The stock’s 50 day moving average price is $4.03 and its 200 day moving average price is $4.24.

Chromadex (NASDAQ:CDXC) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Chromadex had a negative net margin of 85.86% and a negative return on equity of 136.15%. The company had revenue of $11.10 million during the quarter, compared to the consensus estimate of $10.81 million. Research analysts predict that Chromadex will post -0.5 EPS for the current year.

Several large investors have recently bought and sold shares of the company. Uniplan Investment Counsel Inc. bought a new stake in shares of Chromadex during the second quarter worth about $3,279,000. BlackRock Inc. increased its position in shares of Chromadex by 15.4% during the second quarter. BlackRock Inc. now owns 2,238,654 shares of the company’s stock worth $10,410,000 after acquiring an additional 298,126 shares in the last quarter. Northern Trust Corp increased its position in shares of Chromadex by 0.7% during the second quarter. Northern Trust Corp now owns 416,911 shares of the company’s stock worth $1,939,000 after acquiring an additional 3,090 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Chromadex by 8.1% during the second quarter. Charles Schwab Investment Management Inc. now owns 91,370 shares of the company’s stock worth $425,000 after acquiring an additional 6,880 shares in the last quarter. Finally, Tieton Capital Management LLC increased its position in shares of Chromadex by 5.1% during the second quarter. Tieton Capital Management LLC now owns 1,322,570 shares of the company’s stock worth $6,150,000 after acquiring an additional 64,680 shares in the last quarter. 18.48% of the stock is owned by institutional investors.

Chromadex Company Profile

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.

Featured Article: CD Ladder

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.